Congruence Therapeutics, a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding, announced today the close of an extension to its Series A financing, bringing the total amount …
Trending at Lumira Ventures
Rare Disease Day 2023
Today, February 28th, 2023, is Rare Disease Day. Celebrated internationally, the day is an opportunity to raise awareness and advocate for rare diseases as a human rights priority and work towards a more inclusive society. Over 300 million people globally …
2023 Lumira Venture Innovation Program (VIP): Fellow and Summer Analyst Applications Open
Looking to make a career in life sciences innovation? Our Venture Innovation Program (VIP) is accepting applications for exceptional students across Canada who want to gain exposure to life sciences venture capital and start-ups, and are committed to pushing the …
XyloCor Therapeutics Reports Positive Topline Safety and Efficacy Results from Phase 2 EXACT Clinical Trial of XC001 Novel Gene Therapy for Refractory Angina
No serious adverse events related to drug product were reportedPatients demonstrated improvements in exercise capacity and reductions in episodes of chest painCardiac imaging results provide mechanistic evidence supporting the therapeutic potential of XC001 in cardiovascular disease XyloCor Therapeutics, a clinical-stage …
Cyrano Therapeutics Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of CYR-064 to Treat Post-Viral Smell Loss (Hyposmia)
Currently no FDA-approved therapy for this serious condition Initiation of Phase 2 clinical trial expected to occur in Q2 2023 Cyrano Therapeutics, a biopharmaceutical company developing medicines for patients with hyposmia (smell loss), announced today that the U.S. Food and …
AmacaThera’s Lung Cancer Applications Recognized in QuickFire Challenge
AmacaThera, a clinical-stage biotechnology company developing advanced injectable biomaterials for local, sustained delivery of oncology and pain therapeutics, has received grant funding from the Innovations for Vets QuickFire Challenge: Lung Cancer & Physical Trauma. The program, launched by Johnson & …
Cardiac Dimensions Raises $35 Million in Series D Financing
Funds Expected to Support Enrollment in U.S. Pivotal EMPOWER Trial and European Commercial Expansion for Carillon Mitral Contour System®. Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, …
FDA Grants Fast Track to Edesa Biotech’s ARDS Drug Candidate
Fast Track improves the speed and frequency of communication with FDA, potentially leading to earlier drug approval and access by patients. TORONTO, ON / ACCESSWIRE / December 20, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory …
Deka Biosciences, Inc Announces Submission of Investigational New Drug (IND) Application for Lead Oncology Asset, DK210 (EGFR)
Important Regulatory Milestone Provides Runway to Move DK210 (EGFR) into the Clinical Phase GERMANTOWN, Md., Dec. 27, 2022 /PRNewswire/ — Today, Deka Biosciences, Inc. (Deka), a biotech company focused on developing novel cytokine therapies to treat cancer and inflammatory diseases, announced the submission …
HistoSonics Announces $100 Million in Financings and New Appointment to its Board of Directors
Financings Planned to Support Rapid Expansion of Histotripsy Platform as Company Welcomes Silk Road Medical CEO, Erica Rogers, to its Board of Directors HistoSonics, Inc. (www.histosonics.com), the developer of a non-invasive, novel sonic beam therapy, announced today that it has raised $85 …
World Antimicrobial Awareness Week 2022
Antimicrobial resistance (AMR) occurs when microbes (bacteria, viruses, fungi and parasites) change over time and evolve mechanisms that protect them from the effects of antimicrobials. This process results in microbes no longer responding to medications, making the treatment of infections …
Fusion Pharmaceuticals Appoints Dmitri Bobilev, M.D. As Chief Medical Officer
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Dmitri Bobilev, M.D., as chief medical officer. “We are pleased to welcome Dmitri to Fusion’s leadership team at …
Lumira Ventures Participates In The Closing of PIC Therapeutics $35 Million Series A Financing to Develop Treatments for Drug-Resistant Breast Cancer
Financing Round Led by OrbiMed with participation from Lumira Ventures, Harrington Discovery Institute and existing investors Advent Life Sciences and Belinda Termeer Therapy development focused on addressing a fundamental mechanism in cancer-driving oncogenes October 19, 2022 – PIC Therapeutics, Inc., …
World Mental Health Day 2022
In 2021, Lumira Ventures and Angelini Pharma launched the Angelini Lumira Biosciences Fund (ALBF) to invest in early-stage companies in Canada and U.S. markets that are developing pharmaceutical therapies for central nervous system disorders (CNS) and rare diseases. Through our …
DAMONA Pharmaceuticals Raises US$5.5 Million Seed Stage Financing to Advance Lead Molecule Development to Treat Cognitive Deficits Associated with Depression and Diseases of Aging
TORONTO, Ontario, September 26, 2022 — DAMONA Pharmaceuticals today announced the closing of a seed stage financing round to support the development of its lead therapeutic for the treatment of cognitive symptoms associated with depression and diseases of aging. The …